{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T05:24:58Z","timestamp":1743571498931,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["2021AX002"],"award-info":[{"award-number":["2021AX002"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82074093"],"award-info":[{"award-number":["82074093"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81912-y","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T08:11:59Z","timestamp":1733299919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The anti-tumor effects of main component (benzethonium chloride) of butorphanol tartrate injection in non-small cell lung cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Honglei","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jili","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"1","key":"81912_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L. et al. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"81912_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/0272989X14564432","volume":"35","author":"KA Martinez","year":"2015","unstructured":"Martinez, K. A. et al. Decision regret following treatment for localized breast cancer: Is regret stable over time?. Med. Decis. Making 35(4), 446\u2013457 (2015).","journal-title":"Med. Decis. Making"},{"issue":"4","key":"81912_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10585-017-9862-x","volume":"35","author":"JA Dubowitz","year":"2018","unstructured":"Dubowitz, J. A., Sloan, E. K. & Riedel, B. J. Implicating anaesthesia and the perioperative period in cancer recurrence and metastasis. Clin. Exp. Metastasis 35(4), 347\u2013358 (2018).","journal-title":"Clin. Exp. Metastasis"},{"issue":"9","key":"81912_CR4","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha, A., Dearden, S. & McCormack, R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 5(9), 2892\u20132911 (2015).","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"81912_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"key":"81912_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114206","volume":"208","author":"S Park","year":"2024","unstructured":"Park, S. et al. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer. Eur. J. Cancer 208, 114206 (2024).","journal-title":"Eur. J. Cancer"},{"key":"81912_CR7","doi-asserted-by":"crossref","unstructured":"Ardeshir-Larijani, F. & Ramalingam, S. S. The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC. Nat. Rev. Clin. Oncol., (2024).","DOI":"10.1038\/s41571-024-00938-3"},{"issue":"3","key":"81912_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000060","volume":"1","author":"F Morgillo","year":"2016","unstructured":"Morgillo, F. et al. Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. ESMO Open 1(3), e000060 (2016).","journal-title":"ESMO Open"},{"issue":"7","key":"81912_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","volume":"1","author":"HA Yu","year":"2015","unstructured":"Yu, H. A. et al. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncol. 1(7), 982\u2013984 (2015).","journal-title":"JAMA Oncol."},{"issue":"12","key":"81912_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","volume":"20","author":"AM Tsimberidou","year":"2023","unstructured":"Tsimberidou, A. M. et al. Molecular tumour boards - current and future considerations for precision oncology. Nat. Rev. Clin. Oncol. 20(12), 843\u2013863 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"81912_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(16)00173-X","volume":"17","author":"M Bendixen","year":"2016","unstructured":"Bendixen, M. et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: A randomised controlled trial. Lancet Oncol. 17(6), 836\u2013844 (2016).","journal-title":"Lancet Oncol."},{"key":"81912_CR12","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"81912_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"81912_CR14","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"4","key":"81912_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan, W. C. C. et al. Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. (Lond) 40(4), 135\u2013153 (2020).","journal-title":"Cancer Commun. (Lond)"},{"issue":"6","key":"81912_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen, M. H. et al. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J. Pain Symptom. Manage 51(6), 1070-1090.e9 (2016).","journal-title":"J. Pain Symptom. Manage"},{"issue":"9","key":"81912_CR17","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/cncr.25761","volume":"117","author":"CR Green","year":"2011","unstructured":"Green, C. R., Hart-Johnson, T. & Loeffler, D. R. Cancer-related chronic pain: Examining quality of life in diverse cancer survivors. Cancer 117(9), 1994\u20132003 (2011).","journal-title":"Cancer"},{"issue":"9","key":"81912_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","volume":"10","author":"C Quinten","year":"2009","unstructured":"Quinten, C. et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 10(9), 865\u2013871 (2009).","journal-title":"Lancet Oncol."},{"issue":"11","key":"81912_CR19","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdl183","volume":"17","author":"F Efficace","year":"2006","unstructured":"Efficace, F. et al. Is a patient\u2019s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann. Oncol. 17(11), 1698\u20131704 (2006).","journal-title":"Ann. Oncol."},{"issue":"1","key":"81912_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpainsymman.2009.06.009","volume":"39","author":"SL Beck","year":"2010","unstructured":"Beck, S. L. et al. Core aspects of satisfaction with pain management: Cancer patients\u2019 perspectives. J. Pain Symptom Manage 39(1), 100\u2013115 (2010).","journal-title":"J. Pain Symptom Manage"},{"issue":"6","key":"81912_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch, E. et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J. Clin. Oncol. 34(6), 557\u2013565 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"81912_CR22","first-page":"129","volume":"6","author":"J Vogelsang","year":"1991","unstructured":"Vogelsang, J. & Hayes, S. R. Butorphanol tartrate (stadol): A review. J. Post Anesth. Nurs. 6(2), 129\u2013135 (1991).","journal-title":"J. Post Anesth. Nurs."},{"key":"81912_CR23","doi-asserted-by":"publisher","first-page":"10973","DOI":"10.2147\/OTT.S244928","volume":"13","author":"B Wang","year":"2020","unstructured":"Wang, B. et al. Butorphanol inhibits the malignant biological behaviors of ovarian cancer cells via down-regulating the expression of TMEFF1. Onco. Targets Ther. 13, 10973\u201310981 (2020).","journal-title":"Onco. Targets Ther."},{"issue":"2","key":"81912_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3892\/or.2015.4052","volume":"34","author":"J Wen","year":"2015","unstructured":"Wen, J. et al. Butorphanol, a synthetic opioid, sensitizes ABCB1-mediated multidrug resistance via inhibition of the efflux function of ABCB1 in leukemia cells. Oncol. Rep. 34(2), 755\u2013762 (2015).","journal-title":"Oncol. Rep."},{"key":"81912_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","volume":"137","author":"ACZ Gelatti","year":"2019","unstructured":"Gelatti, A. C. Z., Drilon, A. & Santini, F. C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 137, 113\u2013122 (2019).","journal-title":"Lung Cancer"},{"issue":"1","key":"81912_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12943-020-01202-9","volume":"19","author":"T Zhang","year":"2020","unstructured":"Zhang, T. et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol. Cancer 19(1), 90 (2020).","journal-title":"Mol. Cancer"},{"key":"81912_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biochi.2015.07.024","volume":"118","author":"H Saadi","year":"2015","unstructured":"Saadi, H., Seillier, M. & Carrier, A. The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie 118, 44\u201350 (2015).","journal-title":"Biochimie"},{"issue":"27","key":"81912_CR28","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1038\/onc.2011.25","volume":"30","author":"M Seux","year":"2011","unstructured":"Seux, M. et al. TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene 30(27), 3049\u20133061 (2011).","journal-title":"Oncogene"},{"issue":"39","key":"81912_CR29","doi-asserted-by":"publisher","first-page":"37722","DOI":"10.1074\/jbc.M301979200","volume":"278","author":"R Tomasini","year":"2003","unstructured":"Tomasini, R. et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J. Biol. Chem. 278(39), 37722\u201337729 (2003).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81912-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:04:33Z","timestamp":1733303073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81912-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81912"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81912-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of the Zhejiang Academy of Traditional Chinese Medicine and were conducted according to the Guidelines for the Care and Use of Animals for Scientific Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"30194"}}